Development of a binational thyroid cancer clinical quality registry

A protocol paper

Liane J Ioannou, Jonathan Serpell, Joanne Dean, Cino Bendinelli, Jenny Gough, Dean Lisewski, Julie A. Miller, Win Meyer-Rochow, Stan Sidhu, Duncan Topliss, David Walters, John Zalcberg, Susannah Ahern

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Introduction The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. In 2014, a total of 2693 Australians and 302 New Zealanders were diagnosed with thyroid cancer, with this number projected to rise to 3650 in 2018. The purpose of this protocol is to establish a binational population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. Methods and analysis The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) aims to capture clinical data for all patients over the age of 16 years with thyroid cancer, confirmed by histopathology report, who have been diagnosed, assessed or treated at a contributing hospital. A multidisciplinary steering committee was formed which, with operational support from Monash University, established the ANZTCR in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 20 sites expected to come on board across Australia in 2018. A modified Delphi process was undertaken to determine the clinical quality indicators to be reported by the registry, and a minimum data set was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery and 90-day follow-up. Future plans The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand current practice in the treatment of thyroid cancer and identify variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer term outcome data particularly for patients with poor prognostic disease will add significant further value to the registry.

Original languageEnglish
Article numbere023723
Number of pages8
JournalBMJ Open
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • endocrine tumours
  • quality in health care

Cite this

Ioannou, Liane J ; Serpell, Jonathan ; Dean, Joanne ; Bendinelli, Cino ; Gough, Jenny ; Lisewski, Dean ; Miller, Julie A. ; Meyer-Rochow, Win ; Sidhu, Stan ; Topliss, Duncan ; Walters, David ; Zalcberg, John ; Ahern, Susannah. / Development of a binational thyroid cancer clinical quality registry : A protocol paper. In: BMJ Open. 2019 ; Vol. 9, No. 1.
@article{065a4734583b4966ab32ddbcd5c2dae3,
title = "Development of a binational thyroid cancer clinical quality registry: A protocol paper",
abstract = "Introduction The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. In 2014, a total of 2693 Australians and 302 New Zealanders were diagnosed with thyroid cancer, with this number projected to rise to 3650 in 2018. The purpose of this protocol is to establish a binational population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. Methods and analysis The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) aims to capture clinical data for all patients over the age of 16 years with thyroid cancer, confirmed by histopathology report, who have been diagnosed, assessed or treated at a contributing hospital. A multidisciplinary steering committee was formed which, with operational support from Monash University, established the ANZTCR in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 20 sites expected to come on board across Australia in 2018. A modified Delphi process was undertaken to determine the clinical quality indicators to be reported by the registry, and a minimum data set was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery and 90-day follow-up. Future plans The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand current practice in the treatment of thyroid cancer and identify variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer term outcome data particularly for patients with poor prognostic disease will add significant further value to the registry.",
keywords = "endocrine tumours, quality in health care",
author = "Ioannou, {Liane J} and Jonathan Serpell and Joanne Dean and Cino Bendinelli and Jenny Gough and Dean Lisewski and Miller, {Julie A.} and Win Meyer-Rochow and Stan Sidhu and Duncan Topliss and David Walters and John Zalcberg and Susannah Ahern",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/bmjopen-2018-023723",
language = "English",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "1",

}

Ioannou, LJ, Serpell, J, Dean, J, Bendinelli, C, Gough, J, Lisewski, D, Miller, JA, Meyer-Rochow, W, Sidhu, S, Topliss, D, Walters, D, Zalcberg, J & Ahern, S 2019, 'Development of a binational thyroid cancer clinical quality registry: A protocol paper', BMJ Open, vol. 9, no. 1, e023723. https://doi.org/10.1136/bmjopen-2018-023723

Development of a binational thyroid cancer clinical quality registry : A protocol paper. / Ioannou, Liane J; Serpell, Jonathan; Dean, Joanne; Bendinelli, Cino; Gough, Jenny; Lisewski, Dean; Miller, Julie A.; Meyer-Rochow, Win; Sidhu, Stan; Topliss, Duncan; Walters, David; Zalcberg, John; Ahern, Susannah.

In: BMJ Open, Vol. 9, No. 1, e023723, 01.01.2019.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Development of a binational thyroid cancer clinical quality registry

T2 - A protocol paper

AU - Ioannou, Liane J

AU - Serpell, Jonathan

AU - Dean, Joanne

AU - Bendinelli, Cino

AU - Gough, Jenny

AU - Lisewski, Dean

AU - Miller, Julie A.

AU - Meyer-Rochow, Win

AU - Sidhu, Stan

AU - Topliss, Duncan

AU - Walters, David

AU - Zalcberg, John

AU - Ahern, Susannah

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. In 2014, a total of 2693 Australians and 302 New Zealanders were diagnosed with thyroid cancer, with this number projected to rise to 3650 in 2018. The purpose of this protocol is to establish a binational population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. Methods and analysis The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) aims to capture clinical data for all patients over the age of 16 years with thyroid cancer, confirmed by histopathology report, who have been diagnosed, assessed or treated at a contributing hospital. A multidisciplinary steering committee was formed which, with operational support from Monash University, established the ANZTCR in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 20 sites expected to come on board across Australia in 2018. A modified Delphi process was undertaken to determine the clinical quality indicators to be reported by the registry, and a minimum data set was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery and 90-day follow-up. Future plans The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand current practice in the treatment of thyroid cancer and identify variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer term outcome data particularly for patients with poor prognostic disease will add significant further value to the registry.

AB - Introduction The occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. In 2014, a total of 2693 Australians and 302 New Zealanders were diagnosed with thyroid cancer, with this number projected to rise to 3650 in 2018. The purpose of this protocol is to establish a binational population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. Methods and analysis The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) aims to capture clinical data for all patients over the age of 16 years with thyroid cancer, confirmed by histopathology report, who have been diagnosed, assessed or treated at a contributing hospital. A multidisciplinary steering committee was formed which, with operational support from Monash University, established the ANZTCR in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 20 sites expected to come on board across Australia in 2018. A modified Delphi process was undertaken to determine the clinical quality indicators to be reported by the registry, and a minimum data set was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery and 90-day follow-up. Future plans The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand current practice in the treatment of thyroid cancer and identify variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer term outcome data particularly for patients with poor prognostic disease will add significant further value to the registry.

KW - endocrine tumours

KW - quality in health care

UR - http://www.scopus.com/inward/record.url?scp=85060819247&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2018-023723

DO - 10.1136/bmjopen-2018-023723

M3 - Article

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 1

M1 - e023723

ER -